Remove 2024 Remove Kidney Disease Remove Peripheral Arterial Disease
article thumbnail

2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

Circulation

METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.

article thumbnail

2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

Circulation

METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.

article thumbnail

Injectable Angioplasty Balloon Catheter Transforms Peripheral Procedures, Users Report Reduced Equipment and Contrast Needs

DAIC

Photo: Business Wire milla1cf Thu, 01/18/2024 - 14:05 January 18, 2024 — Summa Therapeutics, LLC announced that the first-in-man injectable angioplasty procedures for patients with below-knee peripheral arterial disease (PAD) were performed successfully using its Finesse Injectable balloon catheter platform. “All

article thumbnail

New Guidelines on Peripheral Artery Disease Issued by American Heart Association, American College of Cardiology and Leading Medical Societies

DAIC

A new joint guideline from the American Heart Association (AHA), the American College of Cardiology (ACC) and nine other medical societies reports early diagnosis and treatment of peripheral artery disease is essential to improve outcomes and reduce amputation risk, heart attack, stroke and death for people with Peripheral Artery Disease (PAD).

article thumbnail

Lowering Atherosclerotic Cardiovascular Disease Events by Treating Residual Inflammatory Risk

DAIC

21-23 hsCRP is nonspecific inflammatory marker and an acute phase reactant that predicts the likelihood of a heart attack, stroke, peripheral artery disease and sudden cardiac death among healthy individuals with no history of CV disease, and recurrent events and death in patients with known ASCVD.22 μ/L on 0.6